A database analysis showed 22% of heart transplant recipients who survived to 1 year and received follow-up were employed full time at 1 year and nearly 33% were employed at 2 years after transplant.
In a retrospective analysis of more than 10,000 heart transplant recipients who survived to 1 year with follow-up, researchers also found that employment at the time of listing or transplantation was strongly associated with employment after surgery. Read the full story in Healio.
Key Takeaways
Evusheld is no longer authorized for use to help prevent COVID-19 in the United States “until further notice,” due to a lack of protection against dominant variants, according to new guidance issued by the FDA.
In its updated guidance, the FDA limited the use of Evusheld (tixagevimab plus cilgavimab, AstraZeneca) to when the combined national frequency of variants that are not susceptible to the treatment is 90% or less. Read more in Healio.
The thought of receiving a lung transplant can prompt a range of emotions
Fear often triggers one’s fight-or flight instincts. Depending on the circumstances, when it happens to me, I’ll either persevere through an unwanted situation or become paralyzed by fear. When I become frozen, I don’t want to do anything, and I let the fear caused by the situation just flush over me.
One of my biggest fears is something that’s pretty common for people with cystic fibrosis (CF): having a lung transplant and rehabbing afterward. Read the full story in Cystic Fibrosis News Today.
The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats opens in a new tab or window is now approved for humans with the disease, drugmaker TheracosBios announced.
As an adjunct to diet and exercise, the oral treatment is indicated for adults with type 2 diabetes, and is not recommended for those with type 1 diabetes or for patients in diabetic ketoacidosis, according to the company. Read the full story in Medpage Today.
Having an organ transplant can feel like a new lease on life!
You find that you can suddenly do more of the things that you enjoy. However, new recipients are sometimes overwhelmed with all the requirements of post-transplant living. Read the full story on CareDx.com.
32-year-old Colleen Barber has partnered with care teams at Loma Linda University International Heart Institute longer than she can remember — from receiving a heart transplant as a baby to recently undergoing a minimally invasive procedure to close a hole called an atrial septal defect (ASD) in her transplanted heart.
Structural interventional cardiologists Jason Hoff, MD, and Amr Mohsen, MD, frequently team up to perform heart procedures that involve repairing or replacing valves and treating other structural abnormalities like holes in the heart. Read the full story from Loma Linda University News.
Absence of a dominant genus, more diversity indicative of better lung function
People with cystic fibrosis (CF) and advanced lung disease who have bacterial communities dominated by just one type of bacteria have a higher risk of lung transplant or death than those with more diverse communities, a study reports.
The risk of needing a lung transplant or death was increased by 80% in patients with low bacterial diversity, compared with those without a dominant genus — a median survival without needing a lung transplant of 1.6 years versus 2.9 years. Read more in Cystic Fibrosis News Today.
Heart disease remained among the leading causes of death, even amid the COVID-19 pandemic, which may have exacerbated preexisting CVD morbidity-related racial/ethnic disparities, researchers reported.
In 2020, more than 3.3 million deaths were registered in the U.S., which exceeded the 2019 figure by more than 500,000 deaths, according to the American Heart Association’s annual Heart Disease and Stroke Statistics update. Read more in Healio.
January 25, 2023 – Researchers at the Children’s Hospital of Philadelphia (CHOP) have developed an application to automate the determination of engraftment, a key outcome after hematopoietic stem cell transplants.
The tool, described in a recent study published in Transplantation and Cellular Therapy, was designed by hematopoietic cell transplant and informatics experts at CHOP to help improve transplant outcomes reporting. According to the press release, the standard method to reduce errors in these reports is a tedious, manual process that is not always effective. Read more in Health IT Analytics.